NeoGenomics, Inc. (NASDAQ:NEO)

COMMUNIQUÉ DE PRESSE

publié le 28/12/2023 à 14:10, il y a 1 année 11 mois

NeoGenomics to Appeal Ruling
NeoGenomics, Inc., a leading oncology testing services company, has announced that its subsidiary, NeoGenomics Laboratories, Inc., will appeal the preliminary injunction issued by the United States District Court for the Middle District of North Carolina. The court's ruling stated that Natera, Inc. has demonstrated a likelihood that products using RaDaR technology infringe one of its patents. However, the order allows patients already using RaDaR to continue their use and permits ongoing research projects, studies,
COMMUNIQUÉ DE PRESSE

publié le 05/12/2023 à 14:00, il y a 1 année 11 mois

NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
NeoGenomics, Inc. to present new data at San Antonio Breast Cancer Symposium highlighting utility of RaDaR for therapy response. The data includes an updated analysis of the TRACER study and the announcement of receipt of the first samples from the SURVIVE clinical trial

NeoGenomics RaDaR Assay San Antonio Breast Cancer Symposium TRACER Study SURVIVE Clinical Trial
COMMUNIQUÉ DE PRESSE

publié le 14/11/2023 à 13:00, il y a 2 années

NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
COMMUNIQUÉ DE PRESSE

publié le 06/11/2023 à 22:05, il y a 2 années

NeoGenomics Reports Third Quarter 2023 Results
COMMUNIQUÉ DE PRESSE

publié le 24/10/2023 à 13:00, il y a 2 années 1 mois

NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
COMMUNIQUÉ DE PRESSE

publié le 17/10/2023 à 15:20, il y a 2 années 1 mois

NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023

Publié le 04/12/2025 à 18:14, il y a 13 heures 34 minutes

Résiliation d'une convention conclue entre actionnaires
Publié le 04/12/2025 à 18:00, il y a 13 heures 49 minutes

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Publié le 04/12/2025 à 18:00, il y a 13 heures 49 minutes

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Publié le 04/12/2025 à 17:45, il y a 14 heures 4 minutes

Informations relatives au nombre total de droits de vote et d’actions
Publié le 04/12/2025 à 17:45, il y a 14 heures 4 minutes

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

Voir tout LES ECHOS COMFI WIRE

Publié le 05/12/2025 à 02:35, il y a 5 heures 14 minutes

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Publié le 05/12/2025 à 02:30, il y a 5 heures 19 minutes

Klondike Gold Announces AGM Results
Publié le 05/12/2025 à 01:00, il y a 6 heures 49 minutes

BEACN Closes First Tranche of Non-Brokered Private Placement
Publié le 04/12/2025 à 23:05, il y a 8 heures 44 minutes

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Publié le 04/12/2025 à 23:00, il y a 8 heures 49 minutes

NXT Energy Solutions Completes Data Acquisition for SFD Survey

Voir tout ACCESSWIRE

Publié le 05/12/2025 à 07:00, il y a 49 minutes

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Publié le 05/12/2025 à 03:30, il y a 4 heures 19 minutes

CGTN: What makes cooperation between China and France a two-way success
Publié le 04/12/2025 à 23:50, il y a 7 heures 58 minutes

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Publié le 04/12/2025 à 20:25, il y a 11 heures 24 minutes

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Publié le 04/12/2025 à 20:15, il y a 11 heures 34 minutes

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Voir tout EQS

News